MXPA04000176A - Formulacion de nucleo. - Google Patents
Formulacion de nucleo.Info
- Publication number
- MXPA04000176A MXPA04000176A MXPA04000176A MXPA04000176A MXPA04000176A MX PA04000176 A MXPA04000176 A MX PA04000176A MX PA04000176 A MXPA04000176 A MX PA04000176A MX PA04000176 A MXPA04000176 A MX PA04000176A MX PA04000176 A MXPA04000176 A MX PA04000176A
- Authority
- MX
- Mexico
- Prior art keywords
- core
- glucopyranosyl
- metformin
- treatment
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2001/021676 WO2003005991A1 (en) | 2001-07-10 | 2001-07-10 | A core formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04000176A true MXPA04000176A (es) | 2004-10-27 |
Family
ID=21742691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04000176A MXPA04000176A (es) | 2001-07-10 | 2001-07-10 | Formulacion de nucleo. |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1429732A4 (ja) |
JP (1) | JP2004536841A (ja) |
AU (1) | AU2001273310B2 (ja) |
CA (1) | CA2453784A1 (ja) |
MX (1) | MXPA04000176A (ja) |
WO (1) | WO2003005991A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2453775A1 (en) * | 2001-07-10 | 2003-01-23 | Kos Life Sciences, Inc. | Core formulation comprising pioglitazone hydrochloride and a biguanide |
JP2004536841A (ja) * | 2001-07-10 | 2004-12-09 | エアロファーム テクノロジー インコーポレイテッド | コア製剤 |
US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
WO2004069229A1 (en) * | 2003-02-05 | 2004-08-19 | Ipca Laboratories Limited | Dual release anti-diabetic drugs and process of production thereof |
WO2004091587A1 (en) * | 2003-04-17 | 2004-10-28 | Ipca Laboratories Limited | Multiple release anti-diabetic drugs and process of production thereof |
US20050163842A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Rosiglitazone and metformin formulations |
WO2010136847A1 (en) * | 2009-05-26 | 2010-12-02 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Coated metformin with pioglitazone solution |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5356913A (en) * | 1990-02-09 | 1994-10-18 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
US6191162B1 (en) * | 1998-05-28 | 2001-02-20 | Medical Research Institute | Method of reducing serum glucose levels |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
WO2001035940A2 (en) * | 1999-11-16 | 2001-05-25 | Smithkline Beecham P.L.C. | Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
US6780432B1 (en) * | 2000-05-01 | 2004-08-24 | Aeropharm Technology, Inc. | Core formulation |
CA2453775A1 (en) * | 2001-07-10 | 2003-01-23 | Kos Life Sciences, Inc. | Core formulation comprising pioglitazone hydrochloride and a biguanide |
JP2004536841A (ja) * | 2001-07-10 | 2004-12-09 | エアロファーム テクノロジー インコーポレイテッド | コア製剤 |
-
2001
- 2001-07-10 JP JP2003511799A patent/JP2004536841A/ja active Pending
- 2001-07-10 EP EP01952575A patent/EP1429732A4/en not_active Withdrawn
- 2001-07-10 CA CA002453784A patent/CA2453784A1/en not_active Abandoned
- 2001-07-10 WO PCT/US2001/021676 patent/WO2003005991A1/en not_active Application Discontinuation
- 2001-07-10 AU AU2001273310A patent/AU2001273310B2/en not_active Ceased
- 2001-07-10 MX MXPA04000176A patent/MXPA04000176A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2453784A1 (en) | 2003-01-23 |
WO2003005991A1 (en) | 2003-01-23 |
EP1429732A1 (en) | 2004-06-23 |
JP2004536841A (ja) | 2004-12-09 |
AU2001273310B2 (en) | 2004-10-07 |
EP1429732A4 (en) | 2005-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6524621B2 (en) | Core formulation | |
US6403121B1 (en) | Core formulation | |
US6451342B2 (en) | Core formulation comprised of troglitazone and a biguanide | |
US6780432B1 (en) | Core formulation | |
US6296874B1 (en) | Core formulation comprising troglitazone and abiguanide | |
IL158506A (en) | Pharmaceutical dosage form for oral administration once daily that combines metformin and at least one other anti-diabetic active ingredient | |
WO2004045608A9 (en) | Pharmaceutical compositions containing a biguanide-glitazone combination | |
US6461639B2 (en) | Core formulation | |
US9370481B2 (en) | Compositions and methods for inhibiting gastric acid secretion | |
WO2007007757A1 (ja) | PPARγアゴニストを含有する医薬組成物 | |
AU2001273310B2 (en) | A core formulation | |
AU2001273289B2 (en) | Core formulation comprising pioglitazone hydrochloride and a biguanide | |
AU2001257456B2 (en) | A core formulation | |
AU2001273310A1 (en) | A core formulation | |
AU2001273289A1 (en) | Core formulation comprising pioglitazone hydrochloride and a biguanide | |
AU2001257456A1 (en) | A core formulation | |
AU2001273290B2 (en) | Core formulation comprising troglitazone and a biguanide | |
AU2001273290A1 (en) | Core formulation comprising troglitazone and a biguanide |